ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals

ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals

Abstract Background The current chemotherapy regimens may extend survival for patients with metastatic bladder cancer (BCa) for a few months, but eventually most patients succumb to disease because they develop resistance to their chemotherapy. Methods TCGA human clinical sample survey and urothelia...

Full description

Bibliographic Details
Main Authors: Chi-Ping Huang, Jinbo Chen, Chi-Cheng Chen, Guodong Liu, Yong Zhang, Edward Messing, Shuyuan Yeh, Chawnshang Chang
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Bladder cancer
Androgen receptor
NF-κB
ASC-J9®
Cisplatin
Online Access:http://link.springer.com/article/10.1186/s13046-019-1258-0

Internet

http://link.springer.com/article/10.1186/s13046-019-1258-0

Similar Items